Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jun 09, 2020
Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1 (PH1) is a rare disorder that affects kidneys due to an excess buildup of oxalate, which in normal cases is filtered through the kidneys...
Read More...
May 26, 2020
Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19. The company has submitted the IND with the US FDA for its planned multinational Phase 2b/3 study of its repurposed drug NP-120 (Ifenprodil) for the treatment of patients ...
Read More...
May 21, 2020
CanSino adds mRNA with Precision NanoSystems CanSino Biologics is already evaluating a recombinant coronavirus vaccine in China. However, it is adding the mRNA to COVID-19 vaccine through a licensing agreement with Precision NanoSystems. The partners will work on an mRNA nanoparticle vaccine for COVID-1...
Read More...
May 14, 2020
Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising. The drug limited tumour growth in 43% and shrank tumors in 28% of patients...
Read More...
May 07, 2020
Avrobio taps ADC of Magenta for enhancing gene therapy conditioning Avrobio is working to make conditioning safer. The company is collaborating with Magenta Therapeutics to check antibody-drug conjugate. Under the agreement, the partners will evaluate Magenta’s lead conditioning program, MGTA-117, with at lea...
Read More...
Apr 30, 2020
Remdesivir of Gilead accelerates COVID-19 recovery Gilead Sciences' Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery time for hospitalized COVID-19 patients by four days or 31% as published in a National Institutes of Health-sponsored study setting the drug against p...
Read More...
Apr 14, 2020
Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients. The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...
Read More...
Apr 02, 2020
Niacin might help in combating Glioblastoma Glioblastomas are difficult to treat in part as the brain’s immune cells are stifled and unable to attack against tumors. A research team of the University of Calgary in Canada revealed that a common vitamin might help resolve the issue. The researchers presen...
Read More...
Mar 26, 2020
FDA permits COVID-19 treatments with blood from survivors The FDA revealed the convalescent plasma use that is derived from the donated blood of people that have recovered from COVID-19 and that might have beneficial antibodies. It is being used as an investigational treatment for patients with severe cases of t...
Read More...
Mar 24, 2020
Thermo Fisher Scientific has announced to invest a hefty amount worth USD 800 Million across pharma manufacturing and services. The company plans to expand its capabilities in pharma manufacturing and services in the coming two years, with USD 475 Million reserved for 2020. The company has been acquirin...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper